Nationwide Commercial Laboratory Seroprevalence Survey

CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2.

This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#national-lab.

Additional information is available at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html.

Data and Resources

Field Value
accessLevel public
bureauCode {009:20}
catalog_@context https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld
catalog_@id https://healthdata.gov/data.json
catalog_conformsTo https://project-open-data.cio.gov/v1.1/schema
catalog_describedBy https://project-open-data.cio.gov/v1.1/schema/catalog.json
identifier https://data.cdc.gov/api/views/d2tw-32xv
issued 2020-10-22
landingPage https://data.cdc.gov/d/d2tw-32xv
license https://www.usa.gov/government-works
modified 2021-04-27
programCode {009:020}
publisher Centers for Disease Control and Prevention
resource-type Dataset
source_datajson_identifier true
source_hash 737574f74afd51a1a80465e6d06f22db33ad1573
source_schema_version 1.1
theme {"Laboratory Surveillance"}
Groups
  • AmeriGEOSS
  • National Provider
  • North America
Tags
  • amerigeo
  • amerigeoss
  • ckan
  • coronavirus
  • covid
  • covid-19
  • covid19
  • geo
  • geoss
  • laboratory
  • national
  • north-america
  • prevalence
  • seroprevalence
  • serosurveys
  • united-states
isopen False
license_id other-license-specified
license_title other-license-specified
maintainer Surveillance Review and Response Group
maintainer_email eocevent394@cdc.gov
metadata_created 2025-11-22T16:05:26.515540
metadata_modified 2025-11-22T16:05:26.515544
notes CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2. This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at <a href="https://covid.cdc.gov/covid-data-tracker/#national-lab">https://covid.cdc.gov/covid-data-tracker/#national-lab</a>. Additional information is available at <a href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html">https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html</a>.
num_resources 4
num_tags 16
title Nationwide Commercial Laboratory Seroprevalence Survey